Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two scientific presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held May 16-19, 2022 in Washington, D.C. and virtually. “We have demonstrated the flexibility of our hydrogel platform across multiple ophthalmic i